Zydus Cadila seeks DCGI nod for Hepatitis drug use in C-19 patient

The drug, originally approved for use in chronic hepatitis B and C patients

VG Somani DCGI
Dr. VG Somani, DCGI

New Delhi: Zydus Cadila has submitted its application to Dr V.G. Somani the Drugs Controller General of India (DCGI) for the repurposing of hepatitis drug PegiHep in hospitalised C-19 patients after a phase 3 clinical trial, conducted by the company, showed a single dose was significantly better in treating the acute respiratory disease.

In a phase 3 trial of 250 patients across about two dozen centres in India, Zydus Cadila found that 91.2% of patients treated with the drug were RT-PCR negative by the seventh day as compared to 78.9% in patients given standard of care.

The drug, originally approved for use in chronic hepatitis B and C patients also reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate C-19 patients in the hospital.

Also read:

Latest Notifications: New Drugs and Clinical Trials

Intoxicants: नशे के खिलाफ अभियान में मेडिकल स्टोर सील: Haryana

Johnson & Johnson testing vaccine on teens

Bharat Biotech’s Covaxin: Clinical trials for third dose allowed

No set standards available for Pharma Pollution

Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates